TE-8105 is under clinical development by Immunwork and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TE-8105’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TE-8105 overview
TE-8105 is under development for the treatment of type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH) and obesity. It is a long-acting glucagon-like peptide 1 (GLP-1). It is administered through subcutaneous route.
Immunwork overview
Immunwork is a drug development company that offers research, development and commercialization of a class of new drugs. The company develops drugs for therapeutic diseases such as cancer, autoimmune, osteoporosis, infectious and central nervous system diseases, pathological blood clots, rejection reactions in organ transplantation and other severe clinical conditions. Immunwork’s T-E platform pertains to the molecular platforms for configuring various pharmaceutical molecules, also for the novel combinations of targeting and effector elements used in configuring specific T-E molecules. The company develops multi-arm linker units that are conjugated with small molecules, peptides, proteins and antibody fragments. Immunwork is headquartered in Taipei, Taiwan.
For a complete picture of TE-8105’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
